Dual effect of nicotine in inflammatory diseases
AktualitaGastroent Hepatol 2024; 78(3): 270–271.
LiteraturepdfTofacitinib – is it time for a change in treatment in ulcerative colitis?
AktualitaGastroent Hepatol 2023; 77(1): 78–81.
pdf Kateřina MichnováSecondary failure of biological treatment – a major challenge for biobetters
AktualitaGastroent Hepatol 2022; 76(5): 458–462.
pdf Kateřina MichnováThat’s how time passed with PBC – it is necessary to move one step forward again
AktualitaGastroent Hepatol 2022; 76(4): 359–363.
pdf Kateřina MichnováSubcutaneous Infliximab – the beginning of the era of biobetters in the treatment of immune-mediated inflammatory diseases
AktualitaGastroent Hepatol 2022; 76(3): 268–271.
pdf Kateřina MichnováCan IBD be predicted and possibly prevented?
IBDGastroent Hepatol 2022; 76(3): 264–267.
SummaryLiteraturepdf Ondřej Hradský